Available In Different Color Deferasirox Dispersible 500mg Tablet

With the vast industrial experience in this domain, we are involved in manufacturing, exporting and supplying an exclusive range of Deferasirox Dispersible 500MG Tablet in Hyderabad, Telangana, India. Clients can purchase these products from us at very nominal rates.

Deferasirox 125mg /250mg/ 500mg Dispersible Tablets (DefraTAJ)
Deferasirox Dispersible Tablets (DefraTaj)
100,125,250,400 & 500 MG
Each dispersible tablet contains: Deferasirox. 100 mg, Excipients Q.S.
Each dispersible tablet contains: Deferasirox. 125 mg, Excipients Q.S.
Each dispersible tablet contains: Deferasirox. 250 mg, Excipients Q.S.
Each dispersible tablet contains: Deferasirox. 400 mg, Excipients Q.S.
Each dispersible tablet contains: Deferasirox. 500 mg, Excipients Q.S.

Across a range of anemias, unlock the benefits of once-daily oral DefraTaj in treating chronic iron overload

DefraTaj (deferasirox) binds to iron and removes it from the blood stream. DefraTajis used to treat iron overload caused by blood transfusions in adults and children at least 2 years old.
DefraTaj is a tridentate ligand that binds iron with high affinity, forming a 2:1 complex that is excreted in bile and eliminated primarily via the feces.
DefraTaj is indicated for the treatment of chronic iron overload due to frequent blood transfusions (a Y7 ml/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

DefraTaj is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

in patients with beta thalassemia major with iron overload due to frequent blood transfusions (a Y7 ml/kg/month of packed red blood cells) aged 2 to 5 years in patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older in patients with other anemias aged 2 years and older

DefraTaj is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with nona transfusiona dependent thalassemia syndromes aged 10 years and older.